Author of

• 12824

  +

  P3.21 - Poster Session 3 - Diagnosis and Staging (ID 171)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12836

    +

    P3.21-012 - Institutional Experience In Obtained Biopsy In Patients With NSCLC In One Center In Argentina (ID 3339)

    09:30 - 09:30  |  Author(s): E.A. Richardet
    • Abstract

    Background
    Lung cancer is one of the most common cancers worldwide. It is the leading cause of cancer death in both men and women in the West countries and in Latin America too. In Argentina, 15% of cancer deaths are because of lung cancer (9000 patients per year). The histology and the analysis of EGFR and ALK must be done in all NSCLC. To obtain the tissue, the histological diagnosis and the biological studies is particularly difficult in many centers in our country because we have to send the tissue to other cities. We want to know if we meet the world’s standard in our Institutions. Objetive:The primary objective is to assess whether the material obtained by different methods is enough for correct histopathological diagnosis and molecular biology analysis. We also evaluated the prevalence of different histological subtypes, the prevalence of EGFR mutations in patients with adenocarcinoma, the methodology for obtaining tumor tissue, and the delay in evaluation of EGFR mutation status, and currently in ALK translocations.

    Methods
    A retrospective study analyzed 229 consecutive patients with diagnosed NSCLC in Instituto Oncológico de Cordoba. The diagnostic method used for obtaining tissue was FNA CT-guided in 120 patients (52%), bronchoscopy in 69 (30%), surgery in 29 (13%) and pleural effusion cytology in 11 (5%). EGFR mutations were performed by PCR.

    Results
    A subtype was determined in 218(95%) out of the 229 patients studied; 11(5%) were classified as NOS. 147 patients(64%) were adenocarcinoma, 59(26%) squamous cell carcinoma, 12(5%) large cell carcinoma and 11 carcinoma NOS (5%). In the last period, 66 patients’ tissues with adenocarcinoma were sent for EGFR mutations analysis: In 38 patients (58%), tumor sample was optimal and in 28 (42%) patients, it was suboptimal or inappropriate for analysis. Of patient with optimal sample, 22(34%) presented different mutations and 16 (24%) patients were Wild Type. The time to obtain the result was 1.86 weeks in those with adequate sample (2.1 weeks vs 1.6 weeks for those with insufficient or inadequate sample).

    Conclusion
    In 95% of cases, we could determine the histological subtype and only 5% were NOS. Out of the 66 patients in whom we can evaluate the EGFR, 42% of the samples could not be analyzed due to insufficient material or inadequate fixation and processing techniques. These results are higher but it is not easy to compare them with local and Latin American statistics as they are not enough. The percentage of TKIs sensitivity was 21%, similar to national statistics published (19.3%) and western countries. Latin American average is 33.2% in one study. The time to obtain the results of EGFR mutation is consistent with recent guidelines proposed by the International Association for the Study of Lung Cancer. In our region, we have to work hard in multidisciplinary issues to obtain appropriate tissues in NSCLC.